Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT05287126 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05287126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05287126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2022
Completion date
July 10, 2033
Enrollment
36 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis